| Literature DB >> 28761180 |
Junjie Yang1,2, Xiaobo Yang1, Carlo N De Cecco2, Taylor M Duguay2, Zhiye Chen3, Christian Tesche2, U Joseph Schoepf2, Yundai Chen4.
Abstract
Recent studies demonstrated that sinogram affirmed iterative reconstructions (SAFIRE) can produce higher-resolution images with greater robustness for the reduction of various imaging artefacts. Eighty-five patients were prospectively evaluated and underwent a high-pitch spiral acquisition CT scan. In-stent noise, signal-to-noise ratio(SNR), stent-lumen attenuation increase ratio (SAIR), and subjective image quality score were measured and compared between the SAFIRE and Filter back projection (FBP) reconstructions. Conventional coronary angiography served as the standard of reference. In 159 evaluated stents, SAFIRE was superior to FBP with regards to in-stent noise, SNR, SAIR, and image quality score. On per-stent analysis, SAFIRE vs. FBP reconstruction yielded 85% vs. 85%sensitivity, 89% vs. 78%specificity, 73% vs. 57%positive predictive value, 95% vs. 94%negative predictive value, and 0.87 vs. 0.82 area under curve, although these improvements did not reach statistical significance (P > 0.05). However, in the subgroup of small diameter stents (≤3 mm; n = 95), specificity(82% vs. 62%), positive predictive value(66% vs. 50%) and area under curve (0.81 vs. 0.70) improved significantly (P < 0.05) with SAFIRE. SAFIRE image reconstruction can thus improve the evaluation for ISR, especially in smaller stents.Entities:
Mesh:
Year: 2017 PMID: 28761180 PMCID: PMC5537291 DOI: 10.1038/s41598-017-07499-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Patients’ clinical parameters.
| Characteristics | Data (n = 85) |
|---|---|
| Age (yrs) | 64.5 ± 16 |
| Interval between stent and inclusion (months) | 22 ± 13 |
| Male (n, %) | 50 (59%) |
| Body mass index (kg/m2) | 25 ± 5 |
| Diabetes mellitus (n, %) | 50 (59%) |
| Hypertension (n, %) | 71 (84%) |
| Hypercholesterolemia (n, %) | 62 (73%) |
| Current smoker (n, %) | 29 (34%) |
| Family history (n, %) | 33 (39%) |
Values are n, mean ± SD or n (%).
Image acquisition parameters and stent characteristics.
| Scan Parameters | |
|---|---|
| Tube potential (kVp) | 100 |
| Tube current (mAs) | 273 ± 37 |
| CT dose index volume (mGy) | 5.8 ± 1.9 |
| Z-coverage (cm) | 15.5 ± 3.7 |
| Dose-length product (mGy × cm) | 89.1 ± 16.7 |
| Estimated effective dose (mSv) | 1.4 ± 0.5 |
| Stent Characteristics | |
| No. of stents | 159 |
| Mean No. of stents per patient | 1.87 |
| Mean stents’ diameters, mm | 2.9 ± 0.6 |
| No. of DESs | 119 (86.9%) |
| No. of complex configuration | 76 (47.8%) |
| No. of small stents (≤3 mm) | 95 (59.7%) |
| Mean stent length, mm | 21.3 ± 8.1 |
| Mean stent strut thickness, µm | 110.6 ± 21.1 |
Values are n, mean ± SD or n (%). DESs equaled Drug-Eluting Stents. Complex configuration meant overlapping or bifurcation stenting procedure.
Detailed information for included stents.
| Stent name | n | Strut thickness (μm) | Diameter (mm) | Length (mm) |
|---|---|---|---|---|
| Cypher® (Cordis, Miami, USA) | 25 | 140 | 2.9 ± 0.3 | 23.8 ± 5.2 |
| Endeavor® | ||||
| (Medtronic,Minneapolis, USA) | 28 | 97 | 2.8 ± 0.4 | 21.2 ± 8.4 |
| Partner® (Lepu, Beijing, China) | 30 | 114 | 3.0 ± 0.5 | 22.6 ± 9.7 |
| Firebird (Microport,Shanghai, China) | 40 | 100 | 2.8 ± 0.4 | 19.6 ± 7.6 |
| Others* | 36 | 113.2 ± 42.4 | 3.1 ± 0.5 | 20.1 ± 9.1 |
| Total | 159 | 110.5 ± 22.1 | 3.0 ± 0.4 | 21.4 ± 8.3 |
*Taxus®(Boston Scientific, Natick, USA) n = 6, Excel® (JW Medical System, Shandong, China) n = 7, Lepu BMS®(Lepu) n = 9, Driver® (Medtronic) n = 2, Penta® (Guidant, Indianapolis USA) n = 2, Titan® (Hexacath, Paris, France) n = 5, Zeta® (Guidant) n = 4, Jostent Flex® (JOMED AB, Helsingborg, Sweden) n = 1.
Evaluability performance of HPS-DSCT by SAFIRE.
| SAFIRE(n = 159) | FBP(n = 159) |
| |
|---|---|---|---|
| In-stent noise | 73.2 ± 17.0 | 108.9 ± 22.1 | <0.001 |
| SNR | 21.0 ± 7.9 | 15.7 ± 6.2 | <0.05 |
| SAIR | 22.9 ± 12.8 | 36.4 ± 24.1 | <0.05 |
| Subjective image quality | 3.1 ± 0.7 | 2.4 ± 1.1 | <0.05 |
| Non-diagnostic (n, %) | 4(2.5%) | 9 (5.7%) | <0.05 |
SNR = in-stent signal to noise ratio. SAIR = stent lumen attenuation increase ratio.
Figure 1Example of the presence of in-stent restenosis(3.0 mm Diameter Drug-Eluting Stent). (A) Sinogram affirmed iterative reconstruction dataset with curved multi-planar reconstruction of the right coronary artery (RCA). Arrow indicates the presence of significant in-stent restenosis. Boxed area clarifies the cross-section view. (B) Filtered back projection dataset with curved multi-planar reconstruction of RCA. Arrow indicates the presence of significant in-stent restenosis. Boxed area clarifies the cross-section view. (C) Corresponding conventional coronary angiogram showed significant luminal narrowing (plus 50%) of in-stent patency in the mid part of RCA.
Figure 2Example of the absence of in-Stent restenosis (2.75 mm Diameter Drug-Eluting Stent). (A)Sinogram affirmed iterative reconstruction dataset with curved multi-planar reconstruction of the RCA. It showed no significant in-stent restenosis especially in magnified scale (B,C) Filtered back projection dataset with curved multi-planar reconstruction of the RCA. It showed uncertain in-stent patency even in magnified scale (D,E) Corresponding conventional coronary angiogram confirmed the absence of significant luminal narrowing within the stents.
Diagnostic performance of iterative reconstruction in detecting in-stent patency.
| Total stent (N = 159) | >3 mm stents (N = 64) | ≤3 mm stents (N = 95) | ||||
|---|---|---|---|---|---|---|
| SAFIRE | FBP | SAFIRE | FBP | SAFIRE | FBP | |
| Total | 159 | 159 | 64 | 64 | 95 | 95 |
| TP | 35 | 35 | 12 | 12 | 23 | 23 |
| TN | 105 | 92 | 51 | 52 | 54 | 38 |
| FP | 13 | 26 | 1 | 0 | 12 | 26 |
| FN | 6 | 6 | 0 | 0 | 6 | 6 |
| Sensitivity | 0.85 (0.72,0.93) | 0.85 (0.72,0.93) | 1.00 (0.75,1.00) | 1.00 (0.76,1.00) | 0.79 (0.61,0.90) | 0.79 (0.61,0.90) |
| Specificity | 0.89 (0.82,0.93) | 0.78 (0.70,0.85) | 0.98 (0.90,1.00) | 1.00 (0.93,1.00) | 0.82 (0.71,0.89) | 0.62 (0.50,0.73) |
| PPV | 0.73 (0.59,0.83) | 0.57 (0.45,0.69) | 0.92 (0.67,1.00) | 1.00 (0.76,1.00) | 0.66 (0.49,0.79) | 0.50 (0.36,0.64) |
| NPV | 0.95 (0.89,0.98) | 0.94 (0.87,0.98) | 1.00 (0.93,1.00) | 1.00 (0.93,1.00) | 0.90 (0.80,0.95) | 0.86 (0.73,0.94) |
| AUC | 0.87 (0.81,0.92) | 0.82 (0.75,0.87) | 0.99 (0.93,1.00) | 1.00 (0.94,1.00) | 0.81 (0.71,0.88) | 0.70 (0.60,0.79) |
Values are n or n/N[95% CI]. FBP = Filtered back projection. SAFIRE = sinogram affirmed iterative reconstruction. TP = True Positive. TN = True Negative. FP = False Positive. FN = False Negative. NPV = Negative Predictive Value; PPV = Positive Predictive Value; AUC = Area Under Curve.
Figure 3Calculation of stent-lumen attenuation increase ratio (SAIR). SAIR was calculated using the following equation: stent lumen attenuation increase ratio = (in-stent attenuation − coronary lumen attenuation)/coronary lumen attenuation. Example of coronary lumen attenuation (630 HU) as well as in-stent lumen attenuation (723 HU) measured in a sinogram affirmed iterative reconstruction series. SAIR = (723 − 630)HU/630 HU = 0.148.